With ma­jor back­ing from New York and Chi­na, Athenex sets sights on a $100M can­cer drug IPO

John­son Lau wants to make his come­back as CEO of a pub­lic biotech com­pa­ny, even though the last out­ing 15 years ago didn’t go so well.

Lau and his crew have set their sights on a $100 mil­lion wind­fall for Athenex, a Buf­fa­lo-based can­cer drug de­vel­op­er which has made a com­mit­ment to hire hun­dreds of staffers to win a $200 mil­lion com­mit­ment from the state to fund the con­struc­tion of a new man­u­fac­tur­ing com­plex.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.